Sign inJoin waitlistJoin the waitlist

Robert Canter

Chief, Division of Surgical Oncology · University of California Davis Health

Credentials: · · · · ·

History

Division of Surgical Oncology · University of California Davis Health
Present
University of California Davis Health
Present
University of California Davis Health
Present

Complex General Surgical Oncology
Memorial Sloan Kettering Cancer Center
2005–2007
Surgery
University of Pennsylvania Health System
2000–2005
Hospital of the University of Pennsylvania
1998–2005
Perelman School of Medicine at the University of Pennsylvania
2001–2003
Perelman School of Medicine at the University of Pennsylvania
1994–1998
History, Princeton University, Princeton NJ
1988–1992

Research

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
Nature Medicine · 2019 · 752 citations
Sarcopenia: Current Concepts and Imaging Implications
Review · AJR. American journal of roentgenology · 2015 · 260 citations
NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype
The Journal of Immunology · 2015 · 190 citations

Rick Bold
52 papers
Arta Monjazeb
50 papers · 8 as a resident
Sean Judge
33 papers · 29 as a resident
SM
Steve Martinez
29 papers
Alicia Gingrich
24 papers · 24 as a resident
Sarah Bateni
20 papers · 20 as a resident
Morgan Darrow
18 papers · 1 as a fellow
Steven Thorpe
18 papers · 1 as a fellow
Dariusz Borys
14 papers
Sylvia Cruz
13 papers · 11 as a resident
DS
Dhruvil Shah
12 papers · 11 as a resident
Elizabeth David
12 papers

Grants

UC Davis Comparative Oncology Training Program
National Cancer Institute · T32
PI · $1.8M · University of California at Davis
2020–2031
Targeting Lung Tissue Resident NK Cells with Inhaled IL-15 and TIGIT Blockade in Osteosarcoma
National Cancer Institute · R03
Contact PI · $151K · University of California at Davis
2022–2025
Gene Expression Analysis of Dog Natural Killer Cells Following Immunotherapy with Molecularly Targeted Radionuclide Therapy or Inhaled IL-15
National Cancer Institute · U01
Contact PI · $3M · University of California at Davis
2017–2024
Gene Expression Analysis of Dog Natural Killer Cells as Immunotherapy Target
National Cancer Institute · R03
Contact PI · $157K · University of California at Davis
2021–2024

Clinical trials

Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
Principal investigator · Completed · Phase 1, Phase 2
University of California, Davis
2009–2011